Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222160 | 0.84 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL2224989 | 0.84 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC8HDAC6HPGD | |
| SCHEMBL12403559 | 0.81 | ALDH1A1 (0.46) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 | |
| SCHEMBL2227548 | 0.74 | ALDH1A1 (0.44) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 | |
| SCHEMBL3951956 | 0.71 | ENPP3 (0.53) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 | |
| SCHEMBL21664116 | 0.70 | NOTUM (0.47) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 | |
| SCHEMBL3753522 | 0.68 | RAB9A (0.47) | ALDH1A1HPGDKMT2ANOTUMNPC1 | |
| SCHEMBL5299534 | 0.67 | ALDH1A1 (0.50) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 | |
| SCHEMBL19378458 | 0.67 | HDAC1 (0.51) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 | |
| SCHEMBL243774 | 0.67 | ALDH1A1 (0.55) | ALDH1A1ENPP3ENPP1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| EP-3393458-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GlaxoSmithKline LLC (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112838-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112838-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | ALDH1A1 1152/4885ENPP3 1415/4885ENPP1 3080/4885 |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | HDAC7, HDAC8, HDAC5 | ALDH1A1 1477/4885ENPP3 2057/4885ENPP1 2069/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | ALDH1A1 1152/4885ENPP3 1415/4885ENPP1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.